xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05982093</url>
    </required_header>
    <id_info>
      <org_study_id>PREMIERE (SOLTI-2104)</org_study_id>
      <nct_id>NCT05982093</nct_id>
    </id_info>
    <brief_title>Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer</brief_title>
    <acronym>SOLTI-2104</acronym>
    <official_title>A Phase 2 Randomized Pre-operative,Window of Opportunity Trial Investigating the Effect of Elacestrant With/Without Triptorelin in Premenopausal Patients With HR+/HER2- Breast Cancer - SOLTI-2104-PremiÈRe Trial.</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>SOLTI Breast Cancer Research Group</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>SOLTI Breast Cancer Research Group</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter,&#xD;
        exploratory window of opportunity study in premenopausal women with primary operable&#xD;
        HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of&#xD;
        elacestrant with or without triptorelin.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        PremiÈRe is a 4-week preoperative WOO randomized 2-arms study with a full program in&#xD;
        correlative science, including an accurate estradiol measurement to evaluate the efficacy and&#xD;
        biological activity of elacestrant in premenopausal patients with and without OFS&#xD;
        (elacestrant 400mg per day during 28 days vs elacestrant at 400 mg per day during 28 days&#xD;
        plus triptorelin 3.75mg i.m). Biological information (by tumor biopsy and /or blood sample)&#xD;
        will be obtained at baseline, on day 14 (only blood) and day 28 post-treatment. Endpoints as&#xD;
        rate of CCCA, mean reduction of Ki67 and estrogen-sensitive signature, allowing comparison of&#xD;
        elacestrant activity across populations with and without OFS. Regarding the main objective,&#xD;
        rate of CCCA, and considering the eligible population (ki67 between 10-35%) and unpublished&#xD;
        data from ELIPSE study we estimate around a 20% of CCCA in all randomized patients. It's&#xD;
        worthy to mention that a study using triptorelin as GnRH analog and GCMSMS for E2 measurement&#xD;
        showed that nearly all women at day 14 (24 of out 26) had E2 levels in the postmenopausal&#xD;
        range26, allowing us to compare groups with and without OFS at that early time-point.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 2023</start_date>
    <completion_date type="Anticipated">January 2025</completion_date>
    <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC</measure>
      <time_frame>After 30 days (+7 days) of elacestrant therapy</time_frame>
      <description>Rate of CCCA determined by central assessment by IHC Ki67 (% Ki67 ≤ 2.7%) after 4 weeks of therapy.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC according to baseline research-based PAM50 subtype.</measure>
      <time_frame>After 30 days (+7 days) of elacestrant therapy</time_frame>
      <description>Rate of CCCA determined by central assessment by IHC Ki67 (% Ki67 ≤ 2.7%) after short-term elacestrant therapy with or without OFS for patients Luminal A and Non-Luminal A.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate the antiproliferative activity of elacestrant with or without OFS after -treatment</measure>
      <time_frame>After 30 days (+7 days) of elacestrant therapy</time_frame>
      <description>Mean change in Ki67 measured by IHC Ki67 expression between pre- and post-treatment samples. - Differences in differential expression of proliferative genes</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To identify changes in the research-based PAM50 subtypes pre- and post-treatment samples after treatment</measure>
      <time_frame>After 30 days (+7 days) of elacestrant therapy</time_frame>
      <description>Proportion of patients switching subtype between pre- and post-treatment samples</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate the effect of optimal and suboptimal OFS (E2 level greater than 2.72 pg/mL) in CCCA</measure>
      <time_frame>After 30 days (+7 days) of elacestrant therapy</time_frame>
      <description>Mean change in measured by Ki67 expression between pre- and post-treatment samples and CCCA rate determined by Ki67 ≤ 2.7% between pre- and post-treatment samples of elacestrant therapy with or without OFS</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate levels of E2 in blood.</measure>
      <time_frame>After 14 days (+2 days) of elacestrant therapy</time_frame>
      <description>Mean change of E2 levels between pre- and during treatment (D14) and pre-surgery samples</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate levels of FSH in blood.</measure>
      <time_frame>After 14 days (+2 days) of elacestrant therapy</time_frame>
      <description>Mean change of FSH levels between pre- and during treatment (D14) and pre-surgery samples</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate the safety of the treatments when administered in pre-menopausal patient population.</measure>
      <time_frame>Until End of Study Visit (7-28 days after surgery)]</time_frame>
      <description>Incidence and severity of adverse events, with severity, determined according to NCI CTAE v.5.0.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>To evaluate the tolerability of the treatments when administered in pre-menopausal patient population.</measure>
      <time_frame>Until End of Study Visit (7-28 days after surgery)]</time_frame>
      <description>Change from baseline in targeted clinical laboratory test results, including ECGs</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">48</enrollment>
    <condition>Breast Cancer</condition>
    <condition>HER2-negative Breast Cancer</condition>
    <condition>Hormone Receptor Positive Tumor</condition>
    <condition>Premenopausal Breast Cancer</condition>
    <arm_group>
      <arm_group_label>Elacestrant</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>without ovarian function suppression</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Elacestrant + Triptorelin</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>with ovarian function suppression</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Elacestrant</intervention_name>
      <description>Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).</description>
      <arm_group_label>Elacestrant</arm_group_label>
      <arm_group_label>Elacestrant + Triptorelin</arm_group_label>
      <other_name>Orserdu</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Triptorelin</intervention_name>
      <description>Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.</description>
      <arm_group_label>Elacestrant + Triptorelin</arm_group_label>
      <other_name>Orserdu</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Signed informed consent must be obtained prior to any trial-specific procedure.&#xD;
  &#xD;
            2. Patient is premenopausal at the time of study entry&#xD;
  &#xD;
               Premenopausal status is defined as either:&#xD;
  &#xD;
                 -  Patient had last menstrual period within the last 6 months. OR&#xD;
  &#xD;
                 -  Plasma estradiol and FSH in the premenopausal range, according to local&#xD;
                    laboratory definition.&#xD;
  &#xD;
               Note: Patients who have undergone bilateral oophorectomy are not eligible.&#xD;
  &#xD;
            3. Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast&#xD;
               untreated and recently diagnosed, with all the following characteristics:&#xD;
  &#xD;
                 -  Stage I to stage IIB operable breast cancer (7th Edition of the AJCC). Note:&#xD;
                    Axillary lymph node status must be assessed by fine needle biopsy or core biopsy.&#xD;
                    This procedure at screening will be omitted if there is no suspicion for positive&#xD;
                    axillary lymph node(s) radiographically or if a pathological report of suspicious&#xD;
                    lymph nodes of the results of a fine needle biopsy or core biopsy is available&#xD;
                    prior to the screening period.&#xD;
  &#xD;
                 -  Absence of distant metastasis (i.e., M0) as determined by institutional practice.&#xD;
  &#xD;
                 -  At least 1 lesion that can be accurately and serially measured in at least 1&#xD;
                    dimension and for which the longest diameter is ≥ 10 mm as measured by magnetic&#xD;
                    resonance imaging (MRI) or ultrasound (US).&#xD;
  &#xD;
                 -  In the case of a multifocal tumor, the largest lesion must be ≥ 10 mm and&#xD;
                    designated the &quot;target&quot; lesion for all subsequent tumor evaluations. All biopsied&#xD;
                    tumors had to be ER+HER2-negative&#xD;
  &#xD;
            4. ER-positive with expression higher than 10% and HER2-negative tumor&#xD;
  &#xD;
                 -  HER2 negativity is defined as either of the following: Immunohistochemistry (IHC)&#xD;
                    0, IHC 1+ or IHC2+/in situ hybridization (ISH) negative as per most recent&#xD;
                    American Society of Clinical Oncology (ASCO)-College of American Pathologists&#xD;
                    Guideline (CAP) guideline according to the local laboratory as determined on the&#xD;
                    most recently analyzed tissue sample.&#xD;
  &#xD;
                 -  Documentation of ER positive tumor with ≥ 10% staining by immunohistochemistry of&#xD;
                    cells as per most recent ASCO-CAP guideline according to the local laboratory&#xD;
                    determined on the most recently analyzed tissue sample, with or without&#xD;
                    progesterone receptor positivity.&#xD;
  &#xD;
            5. Ki67 expression ≥ 10% and ≤ 35% by local assessment&#xD;
  &#xD;
            6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
  &#xD;
            7. Breast cancer eligible for primary surgery.&#xD;
  &#xD;
            8. Availability of pre-treatment tumor tissue sample of FFPE tumor block from primary&#xD;
               tumor for biomarker analysis. The tumor tissue should be of good quality based on&#xD;
               total and viable tumor content and must be evaluated centrally for quality prior to&#xD;
               enrollment. Archival tumor tissue or ex professo biopsy are acceptable.&#xD;
  &#xD;
            9. Adequate hematologic and organ function within 14 days before the first study&#xD;
               treatment on Day 1, defined by the following:&#xD;
  &#xD;
                 1. Neutrophils (ANC ≥1.000/μL).&#xD;
  &#xD;
                 2. Hemoglobin ≥ 9.0 g/dL (with no need for transfusions).&#xD;
  &#xD;
                 3. Platelet count ≥ 75. 000/μL.&#xD;
  &#xD;
                 4. Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥30 mL/min&#xD;
                    (Cockcroft-Gault Equation)&#xD;
  &#xD;
                 5. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN and&#xD;
                    activated partial thromboplastin time (aPTT) within therapeutic range.&#xD;
  &#xD;
                    Note: Subjects who are receiving anticoagulation treatment which is monitored by&#xD;
                    INR (eg, warfarin) may be allowed to participate if they have a stable INR (ie,&#xD;
                    within therapeutic range) for at least 28 days prior to the first dose of study&#xD;
                    drug, in the absence of any exclusionary medical conditions, and provided that&#xD;
                    elacestrant would be appropriate therapy for the subject&#xD;
  &#xD;
                 6. Potassium, total Calcium (corrected for serum albumin), and sodium NCI CTCAE v5.0&#xD;
                    Grade ≤ 1.&#xD;
  &#xD;
                 7. Alanine aminotransferase (ALT) ≤ 3x upper limit of normal (ULN)&#xD;
  &#xD;
                 8. Aspartate aminotransferase (AST) ≤ 3x ULN&#xD;
  &#xD;
                 9. Total bilirubin ≤ ULN or total bilirubin ≤ 1.5x ULN with direct bilirubin ≤ ULN&#xD;
                    of the laboratory in subjects with documented Gilbert's Syndrome&#xD;
  &#xD;
           10. Patient must be willing and able to comply with scheduled visits, treatment plans,&#xD;
               laboratory tests, and other trial procedures.&#xD;
  &#xD;
           11. Women of childbearing potential (CBP), defined as all women physiologically capable of&#xD;
               becoming pregnant, must have confirmed negative serum pregnancy test within 7 days&#xD;
               prior to randomization.&#xD;
  &#xD;
           12. Female subjects must not donate, or retrieve for their own use, oocytes from the time&#xD;
               of screening and throughout the study treatment period, and for at least 120 days&#xD;
               after the time of final study drug administration.&#xD;
  &#xD;
           13. Women of CBP must be willing to use highly effective methods of contraception.&#xD;
               Contraception must continue during the trial treatment and after stopping the&#xD;
               treatment received according to protocol. Highly effective contraception methods&#xD;
               include:&#xD;
  &#xD;
                 -  Total abstinence (when this is in line with the preferred and usual lifestyle of&#xD;
                    the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                    post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                    contraception.&#xD;
  &#xD;
                 -  Placement of a non-hormonal intrauterine device (IUD). Notes: Use of oral&#xD;
                    (estrogen and progesterone), transdermal, injected, implanted, hormone containing&#xD;
                    intrauterine system, or any other hormonal methods of contraception is not&#xD;
                    allowed in this trial. Women are considered of CBP unless: they have had ≥ 12&#xD;
                    months of natural (spontaneous) amenorrhea with an appropriate clinical profile&#xD;
                    (i.e., age-appropriate history of vasomotor symptoms) or have had surgical&#xD;
                    bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or&#xD;
                    tubal ligation at least four weeks prior to randomization. In the case of&#xD;
                    oophorectomy alone, only when the reproductive status of the woman has been&#xD;
                    confirmed by follow-up hormone level assessment, she will be considered not of&#xD;
                    CBP. After the end of trial treatment, patients should use effective&#xD;
                    contraception at least until 28 days after therapy discontinuation.&#xD;
  &#xD;
           14. Patients must have the ability to swallow oral medication.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Inoperable locally advanced or inflammatory breast cancer (any stage III).&#xD;
  &#xD;
            2. Metastatic (Stage IV) breast cancer.&#xD;
  &#xD;
            3. Synchronous invasive bilateral or multicentric breast cancer.&#xD;
  &#xD;
            4. Patients requiring immediate neoadjuvant chemotherapy or immediate surgical&#xD;
               intervention.&#xD;
  &#xD;
            5. Patients who have undergone sentinel lymph node biopsy or tumor excisional biopsy&#xD;
               prior to study treatment.&#xD;
  &#xD;
            6. Prior malignancy within 3 years prior to randomization, except curatively treated&#xD;
               non-melanoma skin cancer, in situ cancer or adequately and curatively treated Stage I&#xD;
               or II cancer from which the patient is currently in complete remission.&#xD;
  &#xD;
            7. Patients currently on following medications, which cannot be interrupted 7 days prior&#xD;
               treatment start:&#xD;
  &#xD;
                 -  Any prohibited medication as per decapeptyl (triptorelin) label&#xD;
  &#xD;
                 -  Strong inhibitors of CYP3A4, including grapefruit, grapefruit hybrids, pummelos,&#xD;
                    starfruit and Seville oranges&#xD;
  &#xD;
                 -  Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4&#xD;
                    (Refer to http://medicine.iupui.edu/clinpharm/ddis/) within 5 half-life of the&#xD;
                    drug prior to initiating trial therapy&#xD;
  &#xD;
                 -  Herbal preparations/medications. These include, but are not limited to, St.&#xD;
                    John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone&#xD;
                    (DHEA), yohimbe, saw palmetto, and ginseng within 5 half-life of the drug prior&#xD;
                    to initiating trial therapy&#xD;
  &#xD;
                 -  Vaccination, including but not limited to vaccination against COVID-19, during&#xD;
                    the 7 days prior to randomization.&#xD;
  &#xD;
            8. Any treatment, local or systemic, including prior chemotherapy, ET, targeted therapy,&#xD;
               and/or radiation therapy for the currently diagnosed BC prior to enrollment.&#xD;
  &#xD;
            9. Major surgical procedure or significant traumatic injury within 28 days prior to&#xD;
               randomization.&#xD;
  &#xD;
           10. Assessment by the investigator to be unable or unwilling to comply with the&#xD;
               requirements of the protocol.&#xD;
  &#xD;
           11. Any of the following within 6 months before enrollment: myocardial infarction,&#xD;
               severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE v5.0 Grade ≥ 2,&#xD;
               prolonged QTcF ≥ Grade 2 (i.e., &gt; 480 msec), uncontrolled atrial fibrillation of any&#xD;
               grade, coronary/peripheral artery bypass graft, heart failure ≥ Class II as defined by&#xD;
               the New York Heart Association guidelines, or cerebrovascular accident including&#xD;
               transient ischemic attack.&#xD;
  &#xD;
           12. Child-Pugh Score greater than Class A (i.e., score &gt;6)&#xD;
  &#xD;
           13. Coagulopathy or any history of coagulopathy within the past 6 months, including&#xD;
               history of deep vein thrombosis or pulmonary embolism. However, subjects with the&#xD;
               following conditions will be allowed to participate:&#xD;
  &#xD;
                 1. Adequately treated catheter-related venous thrombosis occurring &gt;28 days prior to&#xD;
                    the first dose of study drug&#xD;
  &#xD;
                 2. Treatment with an anticoagulant, e.g., warfarin or heparin, for a thrombotic&#xD;
                    event occurring &gt; 6 months before enrollment, or for an otherwise stable and&#xD;
                    allowed medical condition (eg, well controlled atrial fibrillation), provided&#xD;
                    dose and coagulation parameters (as defined by local standard of care) are in&#xD;
                    therapeutic range prior to the first dose of study drug and provided that an AI&#xD;
                    would be an appropriate therapy for the subject&#xD;
  &#xD;
           14. Known hypersensitivity to any of the study drugs, including excipients.&#xD;
  &#xD;
           15. Known difficulty in tolerating oral medications or conditions which would impair&#xD;
               absorption of oral medications such as: uncontrolled nausea or vomiting (i.e., CTCAE ≥&#xD;
               Grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction/motility&#xD;
               disorder, malabsorption syndrome, or prior gastric bypass.&#xD;
  &#xD;
           16. History of or clinical evidence of significant co-morbidities that, in the judgment of&#xD;
               the investigator, may interfere with the conduction of the study, the evaluation of&#xD;
               response, or with informed consent.&#xD;
  &#xD;
           17. Previous hormonal treatments for other indications such as osteoporosis, breast cancer&#xD;
               prevention, hormonal substitutive therapy, such as raloxifene, tamoxifen, estrogen,&#xD;
               progestins must have ended at least 12 months prior to trial registration. If a&#xD;
               patient is on natural products known to contain progestins, they must be stopped 14&#xD;
               days prior to beginning study treatment.&#xD;
  &#xD;
           18. Used any prescription medication during the prior 1 month that the investigator judge&#xD;
               is likely to interfere with the study or to pose an additional risk to the patient in&#xD;
               participating.&#xD;
  &#xD;
           19. Female subject who is pregnant or breastfeeding or intends to become pregnant during&#xD;
               the study.&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <minimum_age>35 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Alejandra Nallely Espinosa</last_name>
      <phone>+34620170641</phone>
      <email>alejandra.espinosa@gruposolti.org</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Jordi Canes</last_name>
      <phone>+34690764247</phone>
      <email>jordi.canes@gruposolti.org</email>
    </overall_contact_backup>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 6, 2023</study_first_submitted>
    <study_first_submitted_qc>August 4, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 8, 2023</study_first_posted>
    <last_update_submitted>August 4, 2023</last_update_submitted>
    <last_update_submitted_qc>August 4, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 8, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Breast Neoplasms</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Triptorelin Pamoate</mesh_term>
    </intervention_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05982093
  org study id: PREMIERE (SOLTI-2104)
  nct id: NCT05982093
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter,
        exploratory window of opportunity study in premenopausal women with primary operable
        HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of
        elacestrant with or without triptorelin.
  PremiÈRe is a 4-week preoperative WOO randomized 2-arms study with a full program in
        correlative science, including an accurate estradiol measurement to evaluate the efficacy and
        biological activity of elacestrant in premenopausal patients with and without OFS
        (elacestrant 400mg per day during 28 days vs elacestrant at 400 mg per day during 28 days
        plus triptorelin 3.75mg i.m). Biological information (by tumor biopsy and /or blood sample)
        will be obtained at baseline, on day 14 (only blood) and day 28 post-treatment. Endpoints as
        rate of CCCA, mean reduction of Ki67 and estrogen-sensitive signature, allowing comparison of
        elacestrant activity across populations with and without OFS. Regarding the main objective,
        rate of CCCA, and considering the eligible population (ki67 between 10-35%) and unpublished
        data from ELIPSE study we estimate around a 20% of CCCA in all randomized patients. It's
        worthy to mention that a study using triptorelin as GnRH analog and GCMSMS for E2 measurement
        showed that nearly all women at day 14 (24 of out 26) had E2 levels in the postmenopausal
        range26, allowing us to compare groups with and without OFS at that early time-point.
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study
  primary purpose: Treatment
  masking: None (Open Label)
  measure: To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC
  time frame: After 30 days (+7 days) of elacestrant therapy
  description: Rate of CCCA determined by central assessment by IHC Ki67 (% Ki67 ≤ 2.7%) after 4 weeks of therapy.
  measure: To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC according to baseline research-based PAM50 subtype.
  time frame: After 30 days (+7 days) of elacestrant therapy
  description: Rate of CCCA determined by central assessment by IHC Ki67 (% Ki67 ≤ 2.7%) after short-term elacestrant therapy with or without OFS for patients Luminal A and Non-Luminal A.
  measure: To evaluate the antiproliferative activity of elacestrant with or without OFS after -treatment
  time frame: After 30 days (+7 days) of elacestrant therapy
  description: Mean change in Ki67 measured by IHC Ki67 expression between pre- and post-treatment samples. - Differences in differential expression of proliferative genes
  measure: To identify changes in the research-based PAM50 subtypes pre- and post-treatment samples after treatment
  time frame: After 30 days (+7 days) of elacestrant therapy
  description: Proportion of patients switching subtype between pre- and post-treatment samples
  measure: To evaluate the effect of optimal and suboptimal OFS (E2 level greater than 2.72 pg/mL) in CCCA
  time frame: After 30 days (+7 days) of elacestrant therapy
  description: Mean change in measured by Ki67 expression between pre- and post-treatment samples and CCCA rate determined by Ki67 ≤ 2.7% between pre- and post-treatment samples of elacestrant therapy with or without OFS
  measure: To evaluate levels of E2 in blood.
  time frame: After 14 days (+2 days) of elacestrant therapy
  description: Mean change of E2 levels between pre- and during treatment (D14) and pre-surgery samples
  measure: To evaluate levels of FSH in blood.
  time frame: After 14 days (+2 days) of elacestrant therapy
  description: Mean change of FSH levels between pre- and during treatment (D14) and pre-surgery samples
  measure: To evaluate the safety of the treatments when administered in pre-menopausal patient population.
  time frame: Until End of Study Visit (7-28 days after surgery)]
  description: Incidence and severity of adverse events, with severity, determined according to NCI CTAE v.5.0.
  measure: To evaluate the tolerability of the treatments when administered in pre-menopausal patient population.
  time frame: Until End of Study Visit (7-28 days after surgery)]
  description: Change from baseline in targeted clinical laboratory test results, including ECGs
  arm group label: Elacestrant
  arm group type: Experimental
  description: without ovarian function suppression
  arm group label: Elacestrant + Triptorelin
  arm group type: Active Comparator
  description: with ovarian function suppression
  intervention type: Drug
  intervention name: Elacestrant
  description: Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
  arm group label: Elacestrant
  arm group label: Elacestrant + Triptorelin
  other name: Orserdu
  intervention type: Drug
  intervention name: Triptorelin
  description: Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
  arm group label: Elacestrant + Triptorelin
  other name: Orserdu
  criteria: 
  gender: Female
  minimum age: 35 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Alejandra Nallely Espinosa
  phone: +34620170641
  email: alejandra.espinosa@gruposolti.org
  last name: Jordi Canes
  phone: +34690764247
  email: jordi.canes@gruposolti.org
  responsible party type: Sponsor
  mesh term: Breast Neoplasms
  mesh term: Triptorelin Pamoate